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Abstract
Background: Smokeless tobacco is widely used by athletes to enhance performance. Nicotine is a central nervous system stimulant and acts on
cardiocirculatory and metabolic systems, involving tissue blood flow and circulatory vasoreactivity. The aim of this study was to investigate the effects of
the oral smokeless tobacco (Swedish snus (SS)) on the perception of fatigue and time to exhaustion (TTE) during moderate-intensity aerobic exercise.
Methods: Fourteen healthy non-tobacco male users were recruited for a double-blind, controlled crossover design (SS vs. snus placebo (SP)).
Subjects were tested for 3 sessions: experimental session 1 (Exp1) consisted of an incremental test to determine the maximal aerobic power output
(Wmax), whereas Exp2 and Exp3 consisted of exercising at 65%Wmax until exhaustion in SS or SP conditions. During Exp2 and Exp3, muscle and
cerebral oxygenation was assessed by means of near-infrared spectroscopy, and the rating of perceived exertion (RPE) was recorded.
Results: Comparing SS with SP tests, significant differences (p < 0.05) were found in the values of cerebral (~3%) and muscular tissues
oxygenation (~4%) in the first 30 min of exercise. The RPE values were not significantly different between the 2 conditions (SS vs. SP). No
significant difference was found in TTE (SS: 54.25 ± 21.84 min; SP: 50.01 ± 17.03 min).
Conclusion: This study showed that muscular and cerebral oxygenation increased significantly with snus administration during an endurance
exercise until exhaustion, but this did not affect fatigue perception and TTE. The results showed that snus could not be considered an ergogenic
substance in non-tobacco users.
© 2017 Production and hosting by Elsevier B.V. on behalf of Shanghai University of Sport. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Snus is a smokeless, orally consumed tobacco traditionally pro-
duced and used in Scandinavian countries.1 It is placed between the
upper lip and the gums for approximately 30 min, and then dis-
carded. Sweden is the only country in the European Union granted
special exemption to manufacture and sell snus.2–4 In the USA,
snus was introduced in 2006, and since then an upward trend on its
use has been seen, as reported by Alpert et al.5 An analytical
chemistry study showed that ice hockey players take relevant
amounts of nicotine.6 More recently, Marclay and colleagues7
assessed the amount of nicotine intake in athletes from various
sports by measuring nicotine and metabolite levels following the
analytical chemistry detection. An increased diffusion of this habit
has also been documented in countries where the use of snus has
never been popular. In this regard, some anecdotal reports have
been recently published on the use of snus among alpine skiers in
Italy: 74% of the athletes who practice winter sports have tried
snus at least once and 50% of them continue to use it.8 However, up
to now, no clear evidence is available for sustaining the positive
effect that snus may have on sport performance.
To detect potential patterns of abuse, nicotine was listed in
the World Anti-Doping Agency’s Monitoring Program from
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2012 to 2016.9 It therefore appears important to address the still
unanswered questions on the sought and subjective reinforcing
effects experienced by some athletes. From a psychobiological
standpoint, snus is a delivery system of a psychoactive and
addictive substance, that is, nicotine.10,11 Snus users have posi-
tive expectancies about the potential effects,12 report subjective
pleasure,13 and exhibit dependent behavior and withdrawal
symptoms.14,15 Considering all the issues mentioned above, ath-
letes with the desire to overcome their psychophysical limits are
induced to believe that snus has positive effects on sport
performance.16
Nicotine reduces heart rate variability, increases perception
of mental fatigue and workload, and affects the perceived readi-
ness level among amateur football players who are non-smokers
and non-snus users.17 It also impairs myocardial perfusion
during heart stimulation in healthy non-smokers18 and reduces
stroke volume during submaximal intensity exercise.19 There-
fore, the use of nicotine may negatively affect exercise
capacity.20
Furthermore, data describing the possible effects of smoke-
less tobacco on endurance performance in healthy subjects are
scant. One study has suggested that nicotine, administered by
patch, significantly increases time to exhaustion (TTE) by
~17% during endurance performance.21 However, even if no
effect on fatigue perception was detected when compared with
placebo, the authors suggested that nicotine prolongs TTE via a
central mechanism. Indeed, stimulation of nicotinic cholinergic
receptors (nAChR) releases a variety of neurotransmitters in the
brain.22 One of them, dopamine, has direct effects on brain
microcirculation and underlies blood flow changes of brain
functions.23
In recent years, near-infrared spectroscopy (NIRS) has been
introduced to investigate muscular and prefrontal cortex oxy-
genation during exercise.24 Acute changes of oxyhemoglobin
concentration [O2Hb] connected to the increased cerebral
blood flow are attributed to enhanced neural activation during
exercise24 and mental tasks.25 Hence, NIRS could be used as a
noninvasive tool to monitor the modulatory effect on central
fatigue of a hexogen psychoactive substance like nicotine. Nev-
ertheless, only 2 papers have reported a significant nicotine
effect on neural metabolic activation in animals26 and humans,27
whereas no study has simultaneously investigated the muscular
and cortical oxygenation under smokeless tobacco.
The purpose of this study was to investigate the effects of
snus use during moderate-intensity endurance exercise and on
perception of fatigue. Furthermore, the prefrontal cortex and
muscular perfusion-oxygenation, as well as the cardiovascular
and metabolic responses to exercise, were investigated. We
supposed that nicotine administration through snus might
increase TTE, decrease the perception of effort, and modulate
muscular-cerebral blood perfusion.
2. Methods
2.1. Participants
We recruited 14 healthy male (18–45 years) non-smokers
and non-snus users. Two subjects withdrew from the study
because of a leg injury during the washout week. The following
were the participants’ characteristics (mean ± SD): age = 23.1 ± 4.7
years; height = 178.0 ± 6.1 cm; weight = 74.5 ± 7.1 kg; the
maximal oxygen uptake, VO2max = 48.9 ± 7.6 mL/kg/min;
the maximal mechanical aerobic power output,
Wmax = 316.3 ± 71.1 W; 65%Wmax = 205.6 ± 46.2 W; and
HRmax = 181 ± 9 beats/min. Three participants practiced soccer,
3 practiced running, 2 practiced tennis, and the remaining
participants practiced gymnastics, gym, basketball, and swimming.
2.2. Experimental design
A double-blind, randomized crossover study was designed to
compare the effect of Swedish snus (SS) and snus placebo (SP)
on exercise endurance. The protocol consisted of 3 trials of
cycling exercise. Experiment 1 (Exp1) consisted of an incre-
mental exercise test to determine the Wmax, the VO2max, and the
oxygen uptake and workload (VO2/W) relationship at steady
state. Experiment 2 (Exp2) and Experiment 3 (Exp3) involved
exercising at 65%Wmax until exhaustion. A medical visit was
conducted on the same day of Exp1, and after 3 days all par-
ticipants carried out Exp2. Exp3 took place 1 week after Exp2.
The participants were randomized to blindly receive either SS
or SP on Exp2 or Exp3. All participants were informed about
the procedures and risks of the study and signed an informed
consent. The local ethical committee of the Department of
Neuroscience, Biomedicine and Movement, University of
Verona (Italy), approved the study protocol. The study was
conducted in accordance with the current guidelines of the
Declaration of Helsinki.
2.3. Exercise protocol
The subjects abstained from vigorous physical activity and
alcohol or caffeine consumption during the 24 h before the
tests. All tests were performed in the Exercise Physiology Labo-
ratory of the University of Verona.
2.3.1. Exp1
First, the participants performed a submaximal test on a
cycle-ergometer (Sport Excalibur; Lode, Groningen, The Neth-
erlands) to obtain the VO2/W relationship. Three minutes of rest
were followed by 6 min of warm-up at 0 W, and then the work-
load was set at 30 W and increased by 30 W up to 150 W every
6 min. Pedaling frequency was kept constant at 75 rpm by
means of a visual pacer. After 30 min of rest, a maximal incre-
mental exercise test was performed. The initial workload was
set at 50 W and increased by 30 W every 1 min until voluntary
exhaustion. Voluntary exhaustion was defined as the inability to
maintain the pedaling frequency (60–80 rpm) despite vigorous
encouragement by the experimenters. Heart rate (HR), expira-
tory minute ventilation (VE), and VO2 and CO2 production
(VCO2) were continuously recorded (Quark b2; COSMED,
Rome, Italy). The test was considered maximal if one of the
following criteria was met: (1) final HR was within 10% of
predicted maximum; (2) a clear plateau in oxygen uptake was
noticed; and (3) respiratory exchange ratio (RER = VCO2/VO2)
was equal to, or above, 1.10.28 The global rating of perceived
exertion (RPE) was recorded in the last 15 s of each step using
ARTICLE IN PRESS JSHS356_proof ■ 15 March 2017 ■ 2/8
Please cite this article in press as: Thomas Zandonai, et al., The effects of oral smokeless tobacco administration on endurance performance, Journal of Sport and Health Science (2016),
doi: 10.1016/j.jshs.2016.12.006
2 T. Zandonai et al.
the 15-point Borg scale.29 Wmax was identified as the workload
corresponding to the intersection point between the individual
linear VO2/W relationship and VO2max.
2.3.2. Exp2 and Exp3
To minimize differences and ensure adequate muscle glyco-
gen concentration, the participants were asked to follow a high
carbohydrates diet 24 h before the tests.
The measurement of exhaled carbon monoxide level pro-
vided an immediate method of assessing smoking status, and it
was recorded before each test using the EC50 Micro Smokerlyzer
(Bedfont Scientific Ltd., Maidstone, UK). The participants rested
on the cycle-ergometer for 5 min while baseline measurements
were obtained. Blood samples were taken 3 min before SS or
SP administration to determine blood lactate ([La]b, mmol/L),
blood glucose ([Glu]b, mmol/L), and hemoglobin ([Hb]b, g/dL)
concentrations. SS or SP sachet was placed in the anterior part
of the mouth between the upper gingiva at time zero (T0). The
participants kept the sachets in their mouth until the end of the
exercise. Exercise started at T0 (warm-up) and the subject pedaled
at a constant frequency of 75 ± 5 rpm for 5 min. The workload
was set at 100 ± 50 W to impose the same delta workload
between warm-up and 65%Wmax. At the end of warm-up, the
participants started pedaling at individual 65%Wmax until ex-
haustion. The arteriolar pulse pressure profile at a fingertip
was continuously measured using a noninvasive
photoplethysmographic method (Portapres, FMS, Amsterdam,
The Netherlands). Cardiac output (Q) and stroke volume (SV)
were obtained by means of the Modelflow algorithm (BeatScope
software Version 1.1a; FMS, Amsterdam, The Netherlands).30
Muscle and cerebral oxygenation was continuously recorded
(50 Hz sampling rate) by means of NIRS (OxiplexTS; ISS,
Champaign, IL, USA).31 Muscular NIRS probe was positioned
on the vastus lateralis muscle 15 cm above the patella. NIRS
cerebral probe was positioned on the forehead and attached to
the skin. The forehead side was the opposite of the dominant
leg.24 Tissue oxygenation index (TOI) was calculated as the
ratio between absolute [O2Hb] and total hemoglobin [THb].
All the NIRS variables were normalized with respect to their
related values at rest. RPE was recorded every 5 min until the
end of the test using the 15-point Borg scale.29 Blood samples
to determine [La]b, [Glu]b, and [Hb]b were taken every 10 min
from T0 until the end of the test (Fig. 1).
At the end of the exercise, the participants spat out snus.
Afterwards, we immediately interviewed them about the adverse
events of nicotine (if yes: mild, moderate, or serious). Finally,
5 mL of venous blood was sampled without stasis to assess the
nicotine and cotinine levels.
2.4. Snus and blinding procedure
We administered 8 mg of nicotine in a portion of SS (1.0 g
Catch White Eucalyptus from Swedish Match, Stockholm,
Sweden). SS is a moist oral tobacco product with water content
of 45%–55% and a pH of 8.5.1 The placebo was completely free
of tobacco and nicotine, and had the same pH, fragrance, form,
and appearance as of the SS sachets (1.0 g portion of placebo,
Onico Peppermint from Swedish Match). The SS and SP boxes
were coded and covered so that neither the investigators nor the
participants were aware of the contents.
2.5. Blood sample
Nicotine and cotinine were determined by means of high-
performance liquid chromatography LC-200 pump technique.
[La]b, [Glu]b, and [Hb]b (g/dL) were assessed in arterialized
capillary blood (Biosen C-Line; EKF Diagnostic, Barleben, D,
Germany; and HemoCue Hb 201; HemoCue AB, Ängelholm,
Sweden).
2.6. Statistical analysis
All data were analyzed up to 30 min and at TTE to include
the maximum number of subjects. Exercise data were analyzed
to verify normal distribution using Shapiro-Wilk W test. TTE
data were analyzed using a paired Student’s t test (SS vs. SP).
Respiratory, cardiovascular, and NIRS-derived values were
averaged over a 30 s interval for every 5 min of exercise. Cere-
bral and muscle NIRS data were normalized to baseline concen-
tration values (Δ values). All data were reported as mean ± SD.
A full within 2-way analysis of variance repeated measures
(time × SS/SP) was used to determine the differences in RPE,
cardiorespiratory, blood, and NIRS average values. When signifi-
cant effects were detected, a post hoc analysis was performed
using Bonferroni’s multiple comparison test. Statistical signifi-
cance was always accepted at p < 0.05. Analysis was done using
the Prism 6 statistical software (GraphPad, La Jolla, CA, USA).
3. Results
3.1. Smoking status assessment and nicotine and
cotinine levels
The level of carbon monoxide was 0.9 ± 0.5 ppm before SS
test and 1.0 ± 0.9 ppm before SP test, respectively. The values
were distinctive of non-smokers (<6.5 ppm).32 At the end of the
trials at 65%Wmax, the concentrations of plasma nicotine were
4.49 ± 3.48 ng/mL in SS and 0.50 ± 0.90 ng/mL in SP (Z = 0.0,
−45.0; W = −45; p = 0.039), whereas those of the plasma
cotinine were 27.83 ± 17.65 ng/mL in SS and 5.00 ± 9.04 ng/mL
in SP (Z = 0.0, −66.0; W = −66.0; p = 0.010).
3.2. Adverse events
Five participants reported adverse events at the end of
the experiments at 65%Wmax. One subject reported a mild
Fig. 1. Graphical representation of the experimental protocol in Exp2 and
Exp3. RPE = rating perception of effort (Borg scale29); SP = snus placebo;
SS = Swedish snus.
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discomfort in the throat and another one reported mild nausea
and dizziness at the end of the trial. A moderate nausea and
dizziness was reported by other 3 participants. None reported
adverse events under SP condition.
3.3. Exercise capacity and perceived exertion
The average TTE was 54.25 ± 21.84 min during the SS
session, and 50.01 ± 17.03 min during the SP session. However,
the difference was not statistically significant (p = 0.4503).
Borg scale values at the 10th minute of exercise were sig-
nificantly larger than those assessed every 5 min of exercise in
both Exp2 and Exp3. The mean difference between the 2 scores
was 1.42 ± 0.42 (F(6, 66) = 162.6, p = 0.0090). Although RPE
score kept increasing during exercise, score values were not
significantly different (Fig. 2).
3.4. Lactate, glucose, and hemoglobin concentration
[La]b significantly increased during the first 10 min of exer-
cise from ~1 mmol/L at rest in SS and in SP (p < 0.001) to
remain afterwards stable until TTE. [Glu]b significantly
decreased from rest in SS and SP (p < 0.001). [Hb]b remained
stable from rest to TTE. There were no significant differences
between SS and SP conditions (Table 1).
3.5. Metabolic and respiratory responses
VO2 was, on average, 0.36 L/min at rest in both conditions
and increased during exercise to attain a value of 2.64 ±
0.56 L/min and 2.63 ± 0.59 L/min in SS and SP, respectively. It
slightly increased from the 10th minute of exercise to TTE by
0.16 L/min in SS and by 0.25 L/min in SP (p = 0.9999). No
significant differences between SP and SS were observed
throughout the trials as for VE, VO2, and VCO2. The average
RER during exercise was the same (1.03 ± 0.04) in both SS and
SP.
3.6. Cardiovascular responses
Q at rest was 6.41 ± 0.75 L/min in SS and 6.48 ± 1.05 L/min
in SP; it increased during exercise to 20.2 ± 2.42 L/min in SS
and to 19.36 ± 2.06 L/min in SP. HR at rest was equal to
67.3 ± 7.9 bpm in SS and to 67.3 ± 11.8 bpm in SP; it
increased during exercise to 167.0 ± 11.6 bpm in SS and to
163.1 ± 11.1 bpm in SP. However, Q and HR in SS and SP
conditions were not significantly different during the time trial.
SBP and DBP increased at the exercise onset, reaching their
zenith after the 15th–20th minute of exercise (Fig. 3). DBP at
TTE was significantly smaller in SS (73.10 ± 8.53 mmHg) than
in SP (80.70 ± 8.56 mmHg) (p = 0.0068).
Fig. 2. Borg scale values (mean ± SD) in the first 30 min and at TTE during SS
and SP. *p < 0.05, compared with SP; n = 12. SP = snus placebo; SS = Swedish
snus; TTE = time to exhaustion.
Table 1
Blood sample concentrations of lactate ([La]b), glucose ([Glu]b), and hemoglo-
bin ([Hb]b) in SS and SP conditions before prolonged exercise at baseline and
at exhaustion (mean ± SD).
SS
Pre Post p
[La]b (mmol/L) 0.91 ± 0.21 5.01 ± 3.01 <0.001
[Glu]b (mmol/L) 4.66 ± 0.56 3.86 ± 0.39 <0.001
[Hb]b (g/dL) 17.21 ± 1.35 16.91 ± 0.95 0.328
SP
Pre Post p
[La]b (mmol/L) 1.03 ± 0.42 4.51 ± 2.55 <0.001
[Glu]b (mmol/L) 4.74 ± 0.47 3.79 ± 0.47 <0.001
[Hb]b (g/dL) 16.97 ± 1.26 17.22 ± 1.37 0.264
Abbreviations: SP = snus placebo; SS = Swedish snus.
Fig. 3. SBP (A) and DBP (B) values (mean ± SD) in the first 30 min and at TTE
during SS and SP. **p < 0.01, compared with SP; n = 12. DBP = diastolic blood
pressure; SBP = systolic blood pressure; SP = snus placebo; SS = Swedish snus;
TTE = time to exhaustion.
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3.7. Muscular and cerebral NIRS responses
Cerebral (C) and muscular (M)△TOI, [△THb], and [O2Hb]
values in SS were systematically larger than the ones observed
in SP (Fig. 4A–F).
In particular, TOI (C) was significantly larger in SS than
in SP at the 10th (p = 0.0184), 15th (p = 0.0077), 20th
(p = 0.0096), and 30th (p = 0.0152) minute of exercise
(Fig. 4A); △THb (C) and △O2Hb (C) in SS were significantly
larger than in SP at the 25th minute (p = 0.0256) and at the 10th
minute (p = 0.0166) of exercise, respectively (Fig. 4C and E).
On average, △TOI (M) was significantly greater in SS
than in SP at the 15th minute (p = 0.0213) and 30th minute
(p = 0.0219) of exercise (Fig. 4B). △THb (M) in SS and SP
Fig. 4. Values of △TOI (A, B), △THb (C, D), △O2Hb (E, F), and △HHb (G, H) in the first 30 min of exercise and at TTE during SS and SP measured in the
prefrontal cortex (C) and on vastus lateralis muscle (M) (mean ± SD). *p < 0.05, **p < 0.01, ***p < 0.001, n = 12. HHb = deoxyhemoglobin; O2Hb =
oxyhemoglobin; SP = snus placebo; SS = Swedish snus; TOI = tissue oxygenation index; THb = total hemoglobin; TTE = time to exhaustion.
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significantly differed at the 25th minute (p < 0.001) and 30th
minute (p < 0.001) of exercise (Fig. 4D).△O2Hb (M) in SS was
larger than in SP at the 15th (p = 0.0013), 25th (p < 0.001), and
30th (p < 0.001) minute of exercise and at TTE (p = 0.0260)
(Fig. 4F). Finally, deoxyhemoglobin △HHb(c) and HHb (M)
seemed not to be affected by SS and SP or by the duration of the
exercise (Fig. 4G and H).
4. Discussion
This study investigated the effects of snus administration on
TTE and on the perception of fatigue during endurance exer-
cise. The data showed that tissue (muscular and cerebral) oxy-
genation was significantly altered by nicotine administered
through snus, but TTE and the capacity to sustain aerobic exer-
cise (exercise tolerance)33 were unaffected.
Cerebral △TOI, △[O2Hb], and △[THb] in the prefrontal
cortical areas suggested that cerebral oxygenation was higher in
SS than in SP. This fact supported the hypothesis that nicotine,
acting as a central stimulator, induced a larger cerebral
activity.21 In agreement with this finding, Gehricke et al.27
showed that nicotine administration produced a rapid initial
increase in cerebral △[O2Hb], followed by subsequent
decrease. This effect could be a consequence of the nicotine-
induced dopamine release in the prefrontal cortex via stimula-
tion of nicotinic acetylcholine receptors (nAChR).34 Our data
on cerebral NIRS responses confirmed these findings, as we
found significant differences in the cerebral tissue values from
the 10th to the 30th minute of exercise in SS vs. SP. However,
this probable higher activation did not impact on the exercise
tolerance and TTE.
A parallel effect on muscular tissue was also evident. Mus-
cular △TOI, △[THb], and △[O2Hb] were significantly higher
in SS than in SP in the later stages of exercise, and they
showed a delayed response (25th–30th minute). In particular,
TOI (M) was significantly different at the 15th and 30th minute
of exercise under the effect of SS (plus 4% on the average).
This might be directly related to the increase of muscular
blood flow induced by nicotine during SS, as found in other
studies.35 The higher values of△TOI (M),△[THb], and△[O2Hb]
induced by snus seemed to be a consequence of a potentiated
blood redistribution mechanism mediated by nicotine. Exer-
cise stimulated splanchnic and renal vasoconstriction causing
blood redistribution,36 which was potentiated by nicotine.19 Despite
a better muscle oxygenation obtained with snus administra-
tion, however, there were no improvements in performance at
this exercise intensity.
Individual factors such as tolerance to nicotine effects or
changes in nicotinic acetylcholine receptors’ availability could
influence the response to nicotine absorbed through snus and
may explain these inconclusive results.37 In addition, one can
speculate that the larger corollary discharge that originated
from a larger cortical activation38 might be somehow opposed
by a weaker afferent feedback due to a smaller perturbation of
the muscular milieu.39 The combination of these 2 contrasting
mechanisms could lead to an unchanged TTE.
In our non-smokers and non-snus users, nicotine induced
diastolic hypotension at exhaustion. In 4 studies, SBP and DBP
blood pressure increased in smokeless tobacco users.19,20,37,40
Conversely, others studies reported no effects on blood
pressure.41
Anecdotally, we noticed a relationship between the drop in
DBP and reported adverse events. The diastolic average differ-
ence between subjects with adverse events and subjects with no
adverse events was ~10.5 ± 2.6 mmHg (Fig. 3). Nicotine effect
by smokeless tobacco administration has been reported to lead
to sympathoadrenal activation effect,40,42 which could affect
cardiovascular responses, inducing and increasing blood flow
and resulting in higher HR and blood pressure with muscular
tremor.43 In our subjects, nicotine intake level was pharmaco-
logically equal to a high dose, and it might be responsible for
the significant difference in DBP at TTE.41 Ruiz and Strain44
reported that concentrations of nicotine comparable with the
ones prevailing in our study produced bradycardia, hypoten-
sion, and depressed mental state. Dempsey et al.45 observed that
pharmacokinetic and genetic factors could influence sensitivity
in never-smokers, and this may explain the variable cardiovas-
cular response of our subjects to nicotine.
Statistical analysis indicated a non-significant difference
in RER values at steady state until exhaustion. Therefore, we
might infer that there were no differences on the use of energy
substrates. However, our data did not confirm that the anaerobic
energy turnover might be higher after the administration of
snus, as suggested by Van Duser and Raven’s,19 as no differ-
ences in [La]b were detected in the 2 conditions.
The major point of strength of this study consisted of a novel
evaluation of the psychoactive effects of snus on submaximal
intensity exercise tolerance and fatigue in parallel with the
assessment of several physiological parameters. However, the
study was not without limitations. In particular, it did not
address the possible effects of nicotine in daily snus users under
abstinence and satiety conditions. In addition, Q measured with
Modelflow was not calibrated against values obtained using
gold standard methods. However, it was shown that a non-
calibrated Modelflow method could provide a reliable estimate
of the relative change in Q during submaximal exercise in
healthy young humans.46
This study showed that snus did not modify fatigue percep-
tion during endurance exercise and TTE, suggesting no increase
in endurance performance. However, nicotine intake might
negatively affect cardiovascular responses in non-smoker ath-
letes. For this reason, coaches should monitor athletes on the
use of snus and on nicotine’s addiction properties. Further
investigations on the effects of snus on performance are
required.
5. Conclusion
Despite an increase in cerebral and muscular tissue oxygen-
ation, snus use in healthy, non-smoker participants did not
modify perception of effort and did not increase TTE during
continuous exercise performed at 65% Wmax. Further research is
necessary to test the perception of effort and TTE at higher
exercise intensities (and maybe systematically modulating the
levels of nicotine concentrations). In general, our results
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showed that snus could not be considered an ergogenic sub-
stance at submaximal exercise level.
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